SAN FRANCISCO, May 24, 2016 /PRNewswire/ -- Trianni, Inc. ("TRIANNI"), a biotechnology leader in antibody discovery technology, is pleased to announce Chief Executive Officer and researcher Matthias Wabl, PhD, will be speaking with fellow researchers about the isolation of fully human therapeutic monoclonal antibodies during the 2016 BIO International Convention, June 6 - 9.
"The immune system generates a library of billions of different antibodies, each antibody with a unique specificity. For almost any structure, there will be several different antibodies produced. To isolate the antibody-producing cells of interest, we merely need to expose the host to the antigen of interest and then select. So antibodies offer huge advantages over small chemicals in terms of the efficiency of drug discovery and development," Wabl explains. "The Trianni mouse was created using an extensive gene design approach aimed at maximizing accessible antibody diversity. This gives researchers a path to efficient expression of the full human antibody repertoire and, at the same time, maintains the natural immune response of the wild-type mouse. Validation studies via our major pharma clients and on our own have provided us data showing how effective our mice are over similar platforms for drug development. One client noted, 'In a side-by-side comparison to a competing in-vivo platform, the Trianni Mouse was found to be far superior.'
"We're eager to partner with innovative researchers, and we're interested in talking with them at the 2016 BIO International Convention, June 6-9, here in San Francisco," Wabl says. Company officials will be available for 1:1 meetings during the convention.
For further information and to set up a conversation during the convention, please contact firstname.lastname@example.org or call +1-866-374-9314.
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to enterprise recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Director of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trianni-ceo-to-discuss-next-generation-of-fully-human-therapeutic-monoclonal-antibodies-designed-to-reduce-time-and-cost-of-antibody-isolation-selection-300273875.html
SOURCE Trianni, Inc.